These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 17022826)

  • 21. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy.
    Viani RM; Araneta MR; Deville JG; Spector SA
    Clin Infect Dis; 2004 Sep; 39(5):725-31. PubMed ID: 15356789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
    Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
    HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
    Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
    Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors.
    Corral I; Quereda C; Moreno A; Pérez-Elías MJ; Dronda F; Casado JL; Muriel A; Masjuán J; Alonso-de-Leciñana M; Moreno S
    Cerebrovasc Dis; 2009; 27(6):559-63. PubMed ID: 19390181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simultaneous HAART improves survival in children coinfected with HIV and TB.
    Pensi T; Hemal A; Banerjee T
    Trop Med Int Health; 2012 Jan; 17(1):52-8. PubMed ID: 21967134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.
    Wood E; Montaner JS; Yip B; Tyndall MW; Schechter MT; O'Shaughnessy MV; Hogg RS
    CMAJ; 2003 Sep; 169(7):656-61. PubMed ID: 14517122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area.
    Martínez E; Milinkovic A; Buira E; de Lazzari E; León A; Larrousse M; Loncá M; Laguno M; Blanco JL; Mallolas J; García F; Miró JM; Gatell JM
    HIV Med; 2007 May; 8(4):251-8. PubMed ID: 17461853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan.
    Seyler C; Toure S; Messou E; Bonard D; Gabillard D; Anglaret X
    Am J Respir Crit Care Med; 2005 Jul; 172(1):123-7. PubMed ID: 15805184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.
    Clifford GM; Polesel J; Rickenbach M; Dal Maso L; Keiser O; Kofler A; Rapiti E; Levi F; Jundt G; Fisch T; Bordoni A; De Weck D; Franceschi S;
    J Natl Cancer Inst; 2005 Mar; 97(6):425-32. PubMed ID: 15770006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
    Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
    HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients.
    Napravnik S; Keys JR; Quinlivan EB; Wohl DA; Mikeal OV; Eron JJ
    AIDS; 2007 Apr; 21(7):825-34. PubMed ID: 17415037
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of highly active antiretroviral therapy in South Africa.
    Badri M; Maartens G; Mandalia S; Bekker LG; Penrod JR; Platt RW; Wood R; Beck EJ
    PLoS Med; 2006 Jan; 3(1):e4. PubMed ID: 16318413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of HAART on health status and hospital costs of severe HIV-infected patients: a modeling approach.
    Le Pen C; Rozenbaum W; Downs A; Maurel F; Lilliu H; Brun C
    HIV Clin Trials; 2001; 2(2):136-45. PubMed ID: 11590522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Healthcare resource burden associated with hyponatremia among patients hospitalized for heart failure in the US.
    Amin A; Deitelzweig S; Christian R; Friend K; Lin J; Lowe TJ
    J Med Econ; 2013; 16(3):415-20. PubMed ID: 23336297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hospitalization in HIV in Chicago.
    Sherer R; Pulvirenti J; Stieglitz K; Narra J; Jasek J; Green L; Moore B; Shott S; Cohen M
    J Int Assoc Physicians AIDS Care (Chic); 2002; 1(1):26-33. PubMed ID: 12942666
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of highly active antiretroviral therapy for HIV infection in Taiwan.
    Fang CT; Chang YY; Hsu HM; Twu SJ; Chen KT; Chen MY; Huang LY; Hwang JS; Wang JD
    J Formos Med Assoc; 2007 Aug; 106(8):631-40. PubMed ID: 17711796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medication errors in HIV-infected hospitalized patients: a pharmacist's impact.
    Eginger KH; Yarborough LL; Inge LD; Basile SA; Floresca D; Aaronson PM
    Ann Pharmacother; 2013; 47(7-8):953-60. PubMed ID: 23737513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Costs of health resource utilization among HIV-positive individuals in British Columbia, Canada: results from a population-level study.
    Nosyk B; Lima V; Colley G; Yip B; Hogg RS; Montaner JS
    Pharmacoeconomics; 2015 Mar; 33(3):243-53. PubMed ID: 25404425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of HAART advent on admission patterns and survival in HIV-infected patients admitted to an intensive care unit.
    Casalino E; Wolff M; Ravaud P; Choquet C; Bruneel F; Regnier B
    AIDS; 2004 Jul; 18(10):1429-33. PubMed ID: 15199319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.